Title : Amazing G47 Delta (Herpes Virus) data from Japan for rGBM
link : Amazing G47 Delta (Herpes Virus) data from Japan for rGBM
Amazing G47 Delta (Herpes Virus) data from Japan for rGBM
Dear all,
Just came across a very promising phase II trial interim update from Japan, from Daiichi Sankyo's ongoing G47 Delta trial. It looks like this virotherapy is heading for fast-approval in Japan, after achieving amazing interim results in recurrent GBM:
- 1 yr survival was 92.3% (12/13 patients), vs. around 15% in historical comparisons
- Median PFS (16 people) was 8.6 months; Median OS has not been reached yet (but at least 4 with a 2 year follow-up so far)
While a small population, the results were so strong that the company is seeking to bypass the phase III trial altogether and apply in the near future for manufacturing & marketing of the treatment. Expectation would be to reach conclusion of this process within this year. It would be the first virotherapy treatment on the market.
I did not find anything on it in the English web, but here is the Japanese press release (best us web translate, which works reasonably well):
http://bit.ly/2SAH7Ig
Very good news I believe! Hopefully we can get similar good news this year also from TOCA & DcVax. I really feel like 2019 will finally be a game changer for GBM, finally!
Best,
John
P.S. Does anyone have a view how likely it would be to get this treatment approved outside of Japan given these results?
Just came across a very promising phase II trial interim update from Japan, from Daiichi Sankyo's ongoing G47 Delta trial. It looks like this virotherapy is heading for fast-approval in Japan, after achieving amazing interim results in recurrent GBM:
- 1 yr survival was 92.3% (12/13 patients), vs. around 15% in historical comparisons
- Median PFS (16 people) was 8.6 months; Median OS has not been reached yet (but at least 4 with a 2 year follow-up so far)
While a small population, the results were so strong that the company is seeking to bypass the phase III trial altogether and apply in the near future for manufacturing & marketing of the treatment. Expectation would be to reach conclusion of this process within this year. It would be the first virotherapy treatment on the market.
I did not find anything on it in the English web, but here is the Japanese press release (best us web translate, which works reasonably well):
http://bit.ly/2SAH7Ig
Very good news I believe! Hopefully we can get similar good news this year also from TOCA & DcVax. I really feel like 2019 will finally be a game changer for GBM, finally!
Best,
John
P.S. Does anyone have a view how likely it would be to get this treatment approved outside of Japan given these results?
Thus Article Amazing G47 Delta (Herpes Virus) data from Japan for rGBM
That's an article Amazing G47 Delta (Herpes Virus) data from Japan for rGBM This time, hopefully can give benefits to all of you. well, see you in posting other articles.
You are now reading the article Amazing G47 Delta (Herpes Virus) data from Japan for rGBM with the link address https://polennews.blogspot.com/2019/02/amazing-g47-delta-herpes-virus-data.html
0 Response to "Amazing G47 Delta (Herpes Virus) data from Japan for rGBM"
Post a Comment